跳至主要内容
临床试验/NCT02880306
NCT02880306已完成不适用

Hepatocellular Carcinoma and Rheumatoid Arthritis

Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation0 个研究点目标入组 741,379 人开始时间: 2014年7月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
741,379
主要终点
the risk of developing hepatocellular carcinoma

研究概览

简要总结

Rheumatoid arthritis(RA) is a disorder with altered immunologic function and increased risk of developing malignancies, while studies examining the association between hepatocellular carcinoma (HCC) and RA remain lacking. The investigators aimed to investigate the risk of HCC between participants with and without RA.

详细描述

The investigators did a retrospective, observational, nested case-control study in a cohort that was previously recruited from a population-based RA survey. All participants were enrolled prospectively in Taiwan's national health insurance between Jan 1, 1999, and June 30, 2009, and had follow-up data until Dec 31, 2009. RA was diagnosed based on the 1987 American College of Rheumatology diagnostic criteria. The investigators matched RA and non-RA subjects by propensity score in a 1:1 ratio. The primary outcome was the risk of developing HCC. Cox proportional hazards regression was applied to estimate the hazard ratio (HR) and 95% confidence interval (CI) of HCC for RA and non-RA cohort.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 99 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • subjects were required to have ≥2 RA diagnosis (International Classification of Diseases, Ninth Revision [ICD-9-CM]-codes 714.0x), and to be ≥18 years of age on the date of first diagnosis. And inclusion in the Registry for Catastrophic Illness Patient Database (RCIPD)

排除标准

  • who were diagnosed with RA only once during the study interval, <18 years of age when first diagnosed with RA, first diagnosed with RA after July 1, 2009, or not registered in the RCIPD were excluded

结局指标

主要结局

the risk of developing hepatocellular carcinoma

时间窗: between Jan 1, 1999 and Dec 31, 2009

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

相似试验

Hepatocellular Carcinoma and Rheumatoid Arthritis | 临床试验